Patients with Crohn's disease benefit from treatment with a new platform of immunotherapies designed to restore the body’s innate immune system, a study has found. The announcement was made by Qu Biologics, the company behind the Site Specific Immunomodulators (SSIs).
SSIs are a platform of immunotherapies obtained from components of bacteria and are designed to treat cancer and other immune-related diseases, like ulcerative colitis and Crohn’s disease, by stimulating the body’s immune system. Qu Biologics has advanced multiple SSIs, each of which targets a specific organ or tissue.
The company recently completed a clinical trial on its QBECO SSI as a therapeutic approach for Crohn's disease. The Phase 1/2 placebo-controlled, double-blind study included 68 adult patients with moderate-to-severe Crohn's disease.
Patients were randomized to either QBECO SSI or placebo for the first eight weeks of the study. Participants who responded to treatment continued their therapy for another eight weeks, while those who failed to respond were provided with an "open-label" QBECO treatment for the next eight weeks.
Results reported by Qu Biologics show that after eight weeks of treatment with QBECO SSI, 64% of patients had a statistically significant response, compared to 27% of patients treated with a placebo.
Half of patients, or 50%, achieved clinical remission after being treated for eight weeks, while only 23% of patients treated with a place